Answers are grounded in this paper and cite their sources.
In this article, we review the state of the art knowledge concerning structural and functional imaging in multiple system atrophy (MSA). The relative value of imaging modalities in the differential diagnosis of MSA from other parkinsonian syndromes is debated. It is concluded that, although neuroimaging biomarkers provide valuable supportive data alongside clinical assessments, it is not possible to use them as surrogate markers.
No takes yet. Share an insight, caveat, or question.
Brooks et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: